8/10/2021

Aachen, Germany, & Morristown, N.J., 10 August 2021 – Grünenthal announced today that its U.S. subsidiary, Averitas Pharma Inc., enrolled the first patient in the randomised, double-blind trial AV001. The Phase III study investigates the efficacy, safety, and tolerability of QUTENZA (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) to support an extension of the U.S. label.

7/27/2021

Aachen, Germany, 27 July 2021 – Grünenthal announced today that the first volunteers have been enrolled in a Phase I trial of its Glucocorticoid Receptor Modulator (GRM).

7/20/2021

Aachen, Germany, 20 July 2021 – Grünenthal is deeply saddened by the situation of the people affected by the flood disaster in Germany. Staff and executive management have set up a relief programme to provide immediate support for people who urgently need help.

7/14/2021

Aachen, Germany, 14 July 2021 – Grünenthal, a science-based pharmaceutical company and a leader in pain therapy, announces that the company has successfully extended its existing bond financing by €300 million to a total sum of €950 million.

7/7/2021

Aachen, Germany, 7 July 2021 – Grünenthal, a science-based pharmaceutical company and a leader in pain therapy announced that the company is extending its existing bond financing by €300 million to a total sum of €950 million.

7/6/2021

Aachen, Germany, 06 July 2021 – Grünenthal, a science-based pharmaceutical company and a leader in pain therapy, announced today that it has launched an offering (the “Offering”) of €300,000,000 aggregate principal amount of additional senior secured notes.

5/6/2021

Aachen, Germany, 06 May 2021 – Grünenthal, a science-based pharmaceutical company and a leader in pain therapy, announces that it has successfully closed its first bond transaction.

4/23/2021

Aachen, Germany, 23 April 2021 – Grünenthal GmbH (the “Company”) today announced the pricing of its first bond with an aggregate principal amount of €650 million. Due to strong investor demand, the original offer size was increased by €150 million.

4/12/2021

Aachen, Germany 12 April 2021 – Today, Grünenthal has announced the acquisition of Mestex AG through the takeover of all of its shares and options. Mestex AG is a Swiss biotech company that has developed the innovative investigational medicine MTX-071 (resiniferatoxin) for the intra-articular treatment of pain associated with osteoarthritis of the knee.

4/7/2021

Aachen, Germany, 7 April 2021 –Grünenthal, a global science-based pharmaceutical company, today announced that Sustainalytics, a Morningstar company and a globally-recognized provider of ESG research, ratings and data, has assessed it as having overall medium ESG risk.

3/30/2021

Aachen, Germany, & Morristown, N.J., 30 March 2021 – Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc. will conduct a Phase III trial to study the efficacy, safety and tolerability of QUTENZA (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) with the goal to expand the current U.S. product label.

2/12/2021

Aachen, Germany, 12 February 2021 – Grünenthal has announced the successful extension of its existing €535 million term loan bank facilities. This amendment was conducted in the broader context of the company’s acquisition of the European rights (excluding Spain and the UK) to the lipid-lowering medication CRESTOR™ completed in February 2021.

2/10/2021

Aachen, Germany, 10 February 2021 – Grünenthal today announced the successful completion of its acquisition of the European rights to CRESTOR™ (excluding Spain and the UK) for a total consideration of up to US$ 350 million.

1/12/2021

Aachen, Germany, 12 January 2021 – Florian Dieckmann became Vice President and Head Global Communications at Grünenthal on 1 January 2021. He succeeds Štěpán Kráčala, who transformed the research-driven pharmaceutical company’s Communications department from 2018 until the end of last year.